Non Small Cell Lung Cancer Recurrent Clinical Trial
Official title:
Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors): a Prospective, Single-arm, Phase II Trial
This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Toripalimab combined with Chemotherapy and Antiangiogenic Agents in patients with Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 inhibitors)
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03533127 -
A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03235765 -
Cancer Panel From Blood of Lung Cancer Patients
|
||
| Terminated |
NCT02967133 -
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT05110118 -
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
|
Phase 1 | |
| Recruiting |
NCT05736731 -
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
|
Phase 1/Phase 2 |